Latest Breaking News On - Orphan designated medicinal products - Page 1 : comparemela.com

/PRNewswire/ SIFI, a leading international ophthalmic company, announced today that the pivotal Phase III study on polihexanide 0,08% monotherapy in adults.

John dartSebastiano giuffridaJelle kleijnUniversity college londonHead of clinical developmentInstitute of ophthalmologyEuropean medicines agencyFood drug administrationMarketing authorisation applicationCentralised procedureOrphan designated medicinal productsHonorary clinical professorFabrizio chinesDrug administrationSifi spa